The EU Horizon 2020 SME Instrument phase II grant runs over 33 months and the overall goal of Idogen’s granted application is to perform preclinical safety studies, establish an in-house production capability for manufacture of the tolerogenic vaccine for clinical studies, and perform the first phase I/IIa study in patients with hemophilia A who have inhibitory factor VIII antibodies. The funding will be paid in tranches during the project’s term.
“We are very grateful and proud to be one of the few chosen in the tough competition for funding from the Horizon 2020, SME Instrument. The fact that EU chooses to fund our project is an important confirmation of the potential of our vaccine technology.” CEO Lars Hedbys comments.
About Horizon 2020 – The EU Framework Programme for Research and Innovation
Horizon 2020 is the biggest EU Research and Innovation programme ever, with nearly 80 billion Euro of funding available over 7 years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The goal of the programme is to ensure that Europe produces world-class science, removes barriers to innovation, and facilitates for the public and private sectors to work together in delivering innovation. The SME Instrument is aimed at small and medium-sized businesses and allows financing of individual companies. For additional information about Horizon 2020, see https://ec.europa.eu/programmes/horizon2020/.
For additional information about Idogen, please contact:
Lars Hedbys, CEO
Tel: +46 (0)46-275 63 30
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 18th of May 2017.